Thelansis

Atrial Fibrillation (AF) Market Outlook Thelansis’s “Atrial Fibrillation (AF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrial Fibrillation (AF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s tra...

 Atrial fibrillation (AF) is the most typical sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke. AF causes an estimated 15% of all strokes, and it accounts for one-third of strokes in individuals aged 65 years or older. AF is a complex disease with only a partly elucidated pathophysiology; it is the subject of extensive medical research, believing that a complete understanding of AF will yield novel drug therapies with improved effectiveness and safety profiles over current drugs. In keeping with other forms of cardiac arrhythmia, both a triggering factor and a substrate are thought to be required for AF induction; early-stage research has identified several novel targets that have the potential to prevent abnormal impulse formation (the trigger) and help reverse long-term structural and electrical remodeling. Guidelines pre...

  Atrial fibrillation (AF) is the most typical sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke. AF causes an estimated 15% of all strokes, and it accounts for one-third of strokes in individuals aged 65 years or older. AF is a complex disease with only a partly elucidated pathophysiology; it is the subject of extensive medical research, believing that a complete understanding of AF will yield novel drug therapies with improved effectiveness and safety profiles over current drugs. In keeping with other forms of cardiac arrhythmia, both a triggering factor and a substrate are thought to be required for AF induction; early-stage research has identified several novel targets that have the potential to prevent abnormal impulse formation (the trigger) and help reverse long-term structural and electrical remodeling. Guidelines pr...